1. Introduction {#s0005}
===============

It is known that low water solubility causes a decrease in the release rate of a drug. Thus, the formulation of oral delivery forms of these drugs is a permanent challenge in the pharmaceutical industry. In many cases, the dissolution rate of these drugs is a limiting factor affecting the therapeutic activity. To enhance dissolution several techniques have been developed, such as salt formation, and the development of inclusion complexes and pro-drugs ([@b0080], [@b0105]).

Three categories of dissolution test specifications for immediate release products are described in the guide provided by the Centre for Drug Evaluation and Research at the Food and Drug Administration ([@b0070]): (a) single-point specifications, (b) two-points specifications and (c) dissolution profile comparison. Although this point estimate approach is suitable for drug products containing API with high solubility-high permeability, it may not be adequate for low solubility drugs or for products with modified release characteristics. According to the guide: "*for highly soluble and rapidly dissolving drug products (BCS classes 1 and 3), a single-point dissolution test specification of* 85% (*Q =* 80%) *in* 60 min *or less is sufficient as a routine quality control test for batch-to-batch uniformity"*. For class 2 BSC APIs, it is recommended that a two-point dissolution specification be established, one at 15 min and the other at 30, 45, or 60 min, in order to ensure 85% dissolution ([@b0070]).

Although weight, hardness, content uniformity, friability and disintegration are tests often employed for the analysis of an immediate release solid dosage form, the most important are the quantitation of the API, the determination of impurities and the dissolution test ([@b0030]). Once the dissolution specifications are set for a new drug, based on availability studies, such specifications become official for the development of all subsequent drug products having the same active ingredients. According to good laboratory practices, dissolution is considered one of the most important tests that is to be performed on a solid pharmaceutical dosage form ([@b0030]). This test is also used to control stability of the drug product and batch-to-batch consistency ([@b0070], [@b0010]).

Economic reasons account for the widespread use of generic medicines. Thus, *in vivo* bioequivalence studies are necessary to ensure the existence of therapeutic equivalence between the generic medicine and the original drug product containing the same active drug, except when the drug is highly soluble and highly permeable, i.e., class I BCS compounds.

*In vitro* dissolution profiles can be compared by three groups of methods: (A) methods based on analysis of variance, (B) model-dependent methods, (C) model-independent methods. Dissolution data can either be analysed in their crude form or they can be transformed using simple ANOVA-based methods. The ANOVA is a useful method to detect differences between the profiles in level and shape ([@b0115], [@b0140], [@b0035], [@b0005], [@b0095]).

Model-dependent methods are based on an appropriate curve fitting procedure: the zero and first-order, the Hixson-Crowell, the Higuchi, the quadratic, the Weinbull, the Gompertz and the logistic ([@b0140], [@b0040], [@b0085]). Model-dependent methods explore the mathematical equations governing the liberation profile as a function of certain parameters related to the pharmaceutical dosage form. These models allow an easy quantitative interpretation of data. These methods are always applied in the formulation-development stage.

Model-independent methods generate a single value from a dissolution profile, thus allowing data to be compared directly. Model-independent methods include fit factors and ratio tests. Ratio tests determine, at the same sampling time, the percentage of drug dissolved, the mean dissolution time (MDT) and the dissolution efficiency percentage (DE) of the test formulation in relation with a reference formulation ([@b0090], [@b0025]). Fit factors are known as the difference factor (f~1~) and the similarity factor (f~2~) ([@b0125], [@b0100], [@b0060], [@b0020]).

A class 2 BCS compound is permeable but relatively insoluble. Various techniques have been developed to improve the dissolution rate of class 2 compounds, including micronization, inclusion complex formation, complexation, conversion into amorphous state and solid dispersion ([@b0080]).

According to the FDA, EMA and WHO, the comparison of pharmaceutical products containing class 2 BCS API must be performed by *in vivo* bioequivalence studies.

Meloxicam, 4-hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide is an oxicam derivative with non-steroidal anti-inflammatory properties whose poor water solubility limits its therapeutic efficacy. According to its solubility and permeability, meloxicam belongs to class 2 BCS ([@b0075], [@b0110], [@b0120]).

The aim of the present study was to evaluate and compare the dissolution profile of nine commercial products containing Meloxicam 15 mg. marketed in Argentina, on the basis of their *in vitro* dissolution characteristics using the dissolution conditions in the USP monograph for Meloxicam Tablets ([@b0130]). Our results demonstrate that caution must be exercised as regards interchangeability of generic products.

2. Materials and methods {#s0010}
========================

2.1. Reagents {#s0015}
-------------

Analytical grade potassium dihydrogen phosphate (Biopack, Argentina) and sodium hydroxide (Anedra, Argentina) were used.

Meloxicam was purchased in Unifarma (Argentina), with 99.9% purity, as calculated with reference to the dried substance (India).

2.2. Materials {#s0020}
--------------

Nine commercial brand tablets containing 15 mg meloxicam were purchased from pharmacies in Buenos Aires (Argentina). All tests were performed before the product expiration dates, which were similar among brands.

2.3. Apparatus and procedure {#s0025}
----------------------------

All dissolution studies were performed using USP Apparatus 2 ([@b0130]) in a Vankel, VK 7010 (Varian Inc., USA) manual-sampling dissolution bath. The meloxicam tablets dissolution test was performed at 75 ± 1 rpm in phosphate buffer pH = 7.5. The acceptance criterion was Q = 70% of the labeled amount of meloxicam released in 30 min.

The dissolution medium volume was 900 ml. In all experiments, 10 ml sample aliquots were withdrawn at 5, 15, 30, 45 and 60 min using micropipettes, without medium replacement. The withdrawn amounts were adjusted in the calculations. All samples were filtered through 10.0 µm filter paper (Whatman 91), which was properly validated with the standard solution comparing its performance with that obtained with membrane filters. The drug amount dissolved was determined spectrophotometrically in a Cary 1E Varian UV--VIS spectrophotometer (Victoria, Australia) at 362 nm. To prove peak purity, the second order derivative UV spectra was recorded against dissolution medium as reference solution. This procedure was performed with each product.

Twelve tablets of each preparation were studied to obtain statistically significant results.

### 2.4. Model-dependent methods {#s0030}

Five model-dependent approaches were used to compare the meloxicam dissolution profiles. The model-dependent approaches included the zero order, the first order, the Hixson-Crowell, the Higuchi and the Weibull models.

### 2.4.1. Zero order kinetics {#s0035}

The drug dissolution from pharmaceutical dosage forms that do not disaggregate and deliver the API slowly (assuming that the area is not modified and that no equilibrium conditions are reached) can be represented by the following equation:$$Q_{t} = Q_{0} + K_{0}t$$where Q~0~ is the initial amount of drug in the pharmaceutical dosage form~,~ Q~t~ is the amount of drug in the pharmaceutical dosage form at time *t* and K~0~t is the proportionality constant.

### 2.4.2. First order kinetics {#s0040}

The amount of API delivered from pharmaceutical dosage forms following this dissolution profile are delivered with a rate that is comparable to the amount of API remaining within, in such way that the amount of API liberated per unit of time diminish. First order dissolutions can be represented by the following equation:$$\mathit{\ln}Q_{t} = \mathit{\ln}Q_{0} + K_{0}t$$where Q~0~ is the initial amount of API in the pharmaceutical dosage form~,~ Q~t~ is the amount of API in the pharmaceutical dosage form at time *t* and K~0~ is the proportionality constant

### 2.4.3. Hixson-Crowell model {#s0045}

The Hixson-Crowell model assumes that the particle normal area is comparable to the cubic root of its volume. The following equation represents the dissolution profile:$$Q_{0}^{1/3} + Q_{t}^{1/3} = K_{d}\mspace{6mu} t$$where Q~0~ is the initial amount of API in the pharmaceutical dosage form~,~ Q~t~ is the amount of API in the pharmaceutical dosage form at time *t* and K~d~ is the dissolution constant.

### 2.4.4. Higuchi model {#s0050}

The Higuchi equation is a "square root of time" release kinetics. This kinetic model gives good experimental fitting data in API dissolution processes formulated as modified liberation systems or semisolid dosage forms. This model can be represented by the following equation:$$Q = K_{d}\sqrt{t - t_{0}}$$where K~d~ is the dissolution constant.

### 2.4.5. Weibull model {#s0055}

The Weibull function is a mathematical model lacking physicochemical fundament and can be used to study the dissolution rate. The following equation represents the model:$$\mathbf{\ln}\left( {\mathit{\ln}\frac{Q_{\infty}}{Q_{\infty - Q}}} \right) = \beta\ln(t - t_{0}) - \beta\mathit{lnt}_{d}$$where Q is the amount of API dissolved at time *t*, Q~∞~ is the amount of API dissolved at time infinite, also called "total dissolution", *t*~0~ is the lag time and *t~d~* is the time interval necessary to dissolve or release 63.2% of the API present in the pharmaceutical dosage form. The shape parameter β is obtained from the slope.

To test the pertinence of the release models employed, the Akaike Information Criteria (AIC) ([@b0025]) were used. The AIC are a measure of the best fit based on maximum probability. When comparing data sets, the model associated with the smallest AIC value is considered the best fit. The AIC is only applicable when specimens with equal weighting scheme are compared.$$\mathit{AIC} = n \times \ln(\mathit{WSSR}) + 2p$$where *n* is the number of dissolution data points, *p* is the number of parameters of the model, WSSR is the weight sum of square of residues.

2.5. Model-independent methods {#s0060}
------------------------------

### 2.5.1. Fit factors {#s0065}

Moore and Flanner ([@b0100]) have developed a simple model for independent approximation using fit factors. Fit factors are the difference factor f1, and the similarity factor f2. These fit factors contrast the difference between the percent API dissolved per unit time of a test with that of a reference formulation. Fit factors have been accepted by FDA Centre for Drug Evaluation and Research (CDER) ([@b0070]) and the similarity factor has also been adopted by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) ([@b0060]) and World Health Organization (WHO) ([@b0135]) as a rating criterion of similarity between two *in vitro* dissolution profiles. In Argentina, regulations establish that changes in the post marketing stage as regards dissolution profiles must be evaluated using the similarity factor *f*~2~ ([@b0015]).

The fit factors are denoted f~1~ (difference factor) and f~2~ (similarity factor) and are defined by Eqs. [(7)](#e0035){ref-type="disp-formula"}, [(8)](#e0040){ref-type="disp-formula"}.$$f1 = \left\{ \frac{\left. \sum \middle| R_{t} - T_{t} \right|}{\sum R_{t}} \right\} \times \mspace{6mu} 100\mspace{6mu}\text{where}\mspace{6mu} t = 1\mspace{6mu}\mathit{to}\mspace{6mu} n$$$$f2 = 50\log\left\{ {\left\lbrack {1 + \frac{1}{n}\sum\limits_{t = 1}^{n}{(\mathit{Rt} - \mathit{Tt})}^{2}} \right\rbrack^{- 0.5} \times 100} \right\}$$**(7)** Difference factor **(8)** Similarity factor

where n is the number of dissolution sampling times, and R~t~ and T~t~ are the individual or mean percent dissolved at each time point, *t*, for the reference and test dissolution profiles, respectively. The parameter f~1,~ whose values range from 0 to 15, and f~2,~ whose values range from 50 to 100, are used to define equivalence of two dissolution profiles, which means an average difference ≤10% at each sampling time.

### 2.5.2. Dissolution efficiency {#s0070}

This concept has been presented by Khan and Rhodes in 1972 ([@b0090])). For each sample, the percentage dissolution efficiency is calculated as the percentage ratio of the area under the dissolution curve up to time *t* to that of the area of the rectangle described by 100% dissolution at the same time point, and is defined as follows:$$\mathit{DE}\% = \frac{\mathit{AUC}_{0}^{T}}{Q_{100.T}}100$$

### 2.5.3. Mean dissolution time {#s0075}

The mean dissolution time is determined from the accumulative curves of dissolved API as function of time ([@b0025]).$$\mathit{MDT} = \frac{\Sigma\lbrack t_{i}.\Delta Q_{i}\rbrack}{Q_{\infty}}$$where t~i~ is an intermediate time of the intervals of sampling time, ΔQ~i~ is the amount of API dissolved in every interval of t and Q~∞~ is the maximum of API dissolved.

Results of DE and MDT corresponding to the different meloxicam tablet brands were compared by one-way analysis of variance (ANOVA). The analysis was performed with the Infostat 2008 statistical package ([@b0045]). After this analysis, a multiple-comparisons method (DGC) was applied ([@b0050]).

3. Results and discussion {#s0080}
=========================

*In vitro* dissolution testing is a fundamental analytical methodology in the pharmaceutical industry. This methodology allows quality assurance of solid pharmaceutical forms for oral administration. The lot-to-lot quality assurance fosters the development of new formulations, guarantee quality homogeneity and ensure an acceptable API performance even after being modified. If all these requirements are met, the formulation optimization during the development phase is favoured, and stability studies and manufacturing process quality control can be carried out ([@b0005], [@b0055], [@b0065]).

[Table 1](#t0005){ref-type="table"} summarises the characteristics of the nine products. Brand I was taken as the reference product.Table 1Formulation compositions.BrandOther ingredientsAppearanceISodium citrate, lactose, microcrystalline cellulose, povidone, colloidal silicon dioxide, insoluble povidone, magnesium stearateYellow, circular, with indented line in centreIILactose, microcrystalline cellulose, povidone, insoluble povidone, colloidal silicon dioxide, sodium citrate, sunset yellow aluminum lake, magnesium stearateOrange, circular, with indented line in centreIIILactose monohydrate, sodium citrate, povidone, magnesium stearate, colloidal silicon dioxide, polyethilene glycol 1500, microcrystalline cellulose, crospovidoneYellow, circular, with indented line in centreIVLactose monohydrate, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, sodium citrate dehydrate, magnesium stearate, iron (III) oxide yellowOrange, circular, with indented line in centreVLactose monohydrate, microcrystalline cellulose, sodium citrate trihydrate, povidone K30, colloidal silicon dioxide, crospovidone, magnesium stearateYellow, circular, with indented line in centreVICellactose, crospovidone, povidone K30, sodium citrate, colloidal silicon dioxide, magnesium stearateYellow, circular, with indented line in centreVIICellactose, sodium croscarmellose, colloidal silicon dioxide, sodium citrate dihydrate, magnesium stearateYellow, circular, with indented line in centreVIIISodium citrate, lactose, microcrystalline cellulose, povidone, iron (III) oxide red, colloidal silicon dioxide, crospovidone, magnesium stearateOrange, circular, with indented line in centreIXSodium croscarmellose, sodium lauryl sulfate, cellactose 80, reticulated polyvinylpirrolidone, colloidal silicon dioxide, magnesium stearate, sodium citrateYellow, circular, with indented line in centre.

The dissolution test for meloxicam tablets described in the USP ([@b0130]) indicates that no less than 70% (Q + 5%) of the API should be dissolved in 30 min. [Table 2](#t0010){ref-type="table"} summarises the mean percent dissolved at each time point, the relative standard deviation (RSD), and the upper and lower limits. As shown in [Table 2](#t0010){ref-type="table"}, all Brands fulfilled the USP specifications.Table 2Dissolution data and descriptive statistics of nine meloxicam tablet brands.Time (min)Brandmean%RSDLower limitUpper limitI32.330.414.048.4II24.28.620.827.8III60.39.849.467.7IV59.99.851.766.85V28.78.325.232.0VI69.813.449.782.7VII66.710.156.578.3VIII78.81.976.081.2  IX59.22.656.762.8I66.97.558.674.0II64.28.655.074.2III88.76.577.096.6IV83.05.477.289.215V74.02.571.477.2VI86.97.079.394.8VII89.88.784.9113.3VIII97.82.595.3102.5IX85.04.678.192.9  I83.25.774.488.7II79.58.368.889.0III98.57.083.9109.7IV93.42.888.998.230V92.22.988.696.7VI91.94.387.097.8VII99.73.695.8107.4VIII102.21.799.7105.4IX99.93.092.4105.6  I89.65.780.897.0II95.04.785.8102.8III100.16.988.0112.4IV97.92.493.3102.445V93.91.491.696.1VI93.25.585.3102.0VII98.03.694.4105.6VIII102.22.799.4108.1IX105.04.098.7111.0  I97.03.190.0102.0II98.85.287.1107.0III101.56.289.7114.1IV98.54.389.6107.160V95.32.092.998.8VI96.05.989.2109.5VII98.45.891.4106.4VIII103.00.7101.8104.4IX105.82.6100.0110.4

Dissolution curves indicated that the analysed products presented different dissolution profiles ([Fig. 1](#f0005){ref-type="fig"}). As meloxicam is a class 2 BCS drug, the dissolution test may be formulation-dependent, and the decision related to generics must be made based on the *in vivo* bioequivalence studies.Fig. 1Dissolution profiles of meloxicam tablets.

The dissolution profiles corresponding to the nine products were evaluated by fitting experimental data to the zero and first-order, the Hixson-Crowell, the Higuchi, and the Weibull models. In [Table 3](#t0015){ref-type="table"}, the following parameters are presented: dissolution constants (k) and the determination constant (r^2^), for zero and first order, Hixson-Crowell and Higuchi models, and the shape parameter β, the determination constant (r^2^) and T~d~ which is the time interval necessary to dissolve or release 63.2% of the drug present in the pharmaceutical dosage form, for the Weibull model. No significant variations were found among all β values (β \< 1). The Weibull model provided the best adjustment curve for the nine brands, with the higher determination coefficients (r^2^) and smallest AIC values for all the brands tested (bold print indicating the best fits).Table 3Parameters of the mathematical models and descriptive statistics for the dissolution data.BrandsModelStatisticsIIIIIIIVVVIVIIVIIIIXZero Orderr^2^0.82570.84140.67740.76010.67200.72720.59900.59310.7807k0.13850.16440.08420.08340.13740.05290.06370.04680.1028AIC12.3813.5311.479.3216.495.6310.377.4310.83First Orderr^2^0.95530.96670.80800.86890.79030.82050.64110.68150.9182k0.02680.03190.02440.02200.02680.01430.01790.01800.0350AIC−9.59−9.35−2.40−5.69−1.28−8.17−1.18−2.03−3.68Hixson-Crowellr^2^0.91950.93610.76470.83520.75230.78960.63040.65070.8791k0.01510.01790.01210.01130.01470.00730.00900.00820.0162AIC−14.16−13.71−10.15−13.03−7.82−15.87−9.83−11.27−11.21Higuchir^2^0.92430.93420.81020.87880.80690.84640.74400.73380.8951k1.47781.74640.92830.90391.51800.57510.71530.52501.1102AIC8.229.138.825.9113.852.768.145.317.14Weibullr^2^**0.99850.99550.98960.99610.97450.99340.94700.96350.9866**T~d~13.2514.932.533.2211.601.301.500.322.85β0.42650.53200.27630.25410.47490.16320.21670.17610.3306AIC−**25.20**−**17.60**−**19.95**−**25.68**−**9.97**−**27.51**−**14.00**−**18.03**−**16.86**

The determination of DE and MDT values are useful methods to reduce each curve to a single number, which may be [referred]{.ul} to the dissolution rate constant ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). Statistical differences were found among the brands analysed ([Tables 4a](#t0020){ref-type="table"},[4b.](#t0025){ref-type="table"}, and [5a.](#t0030){ref-type="table"},[5b.](#t0035){ref-type="table"}). The DGC test indicated that brands III, IV, VI and IX were similar, whereas brand VII was similar to brand VIII. MDT values for brands III, IV and VI were found to be similar to each other, whereas brand VII was similar to brand VIII. In both cases, brand I was not found to be similar to any other.Fig. 2Statistical comparison of the Dissolution Efficiency (DE) among the nine commercial products. The average is indicated near the boxes. Bars indicate standard deviation.Fig. 3Statistical comparison of the Mean Dissolution Time (MDT) among the nine commercial products. The average is indicated near the boxes. Bars indicate the standard deviation.Table 4aVariance analysis (ANOVA) of DE Values for the nine pharmaceutical products.Variation sourceSquare sumDegrees of freedomMedium squareF[a](#tblfn1){ref-type="table-fn"}Between treatments3733.058466.6372.67Within treatments635.68996.42Total4368.73107[^1][^2]Table 4bDGC test of DE values for the nine pharmaceutical products.Test:DGC Alfa = 0.05 PCALT = 2.1382*Error: 6.4210 df: 99*BrandsAveragenE.E.II73.25120.73AI75.56120.73BV81.26120.73CIX84.64120.73DIV86.24120.73DVI86.77120.73DIII87.03120.73DVII90.25120.73EVIII91.45120.73ETable 5aVariance analysis (ANOVA) of MDT values for the nine Pharmaceutical products.Variation sourceSquare sumDegrees of freedomMedium squareF[a](#tblfn2){ref-type="table-fn"}Between treatments1885.178235.6577.90Within treatments299.49993.03Total2184.66107[^3][^4]Table 5bDGC test of MDT values for the nine Pharmaceutical products.Test:DGC Alfa = 0.05 PCALT = 1.4676*Error: 3.0251 df: 99*BrandsAveragenE.E.VIII8.35120.50AVII9.37120.50AIII11.61120.50BVI11.62120.50BIV12.13120.50BIX13.31120.50CV16.05120.50DI19.61120.50EII21.31120.50[F]{.ul}

Fit factors are important quantitative parameters recommended by the FDA to compare dissolution profiles ([@b0070]). The results obtained with each brand using brand I as reference are shown in [Table 6](#t0040){ref-type="table"}. The similarity factor f~2~ is more sensitive in finding dissimilarities between dissolution curves than the difference factor f~1~, and the fit factor values are dependent on the number of sampling time point selected. According to the FDA, f~1~ values less that 15 and f~2~ values greater than 50 should ensure equivalence between the dissolution curves, indicating an average difference of no more than 10% at the sample time points. According to this guideline, the dissolution curves corresponding to brand II and brand V would be similar to that obtained with the reference formulation.Table 6Fit factors for the nine brands of meloxicam tablets based on the average of twelve tablets.Fit factorBrandf~1~f~2~I/II6**65I/III**2237**I/IV**1740I/V**762**I/VI1936I/VII2335I/VIII3128I/IX2337

4. Conclusions {#s0085}
==============

This study found variations in the dissolution profiles of meloxicam tablets commercially available in Argentina. The dissolution profiles obtained with the analysed products were found to be quite different from each other, thus demonstrating that the results obtained with the dissolution test are formulation-dependent. All brands fulfilled the specifications of the dissolution test established by the USP 38.

The Weibull model kinetic curve rendered the best adjustment. The best fittings were obtained with brands I, II, IV and VI, with maximum determination coefficients and smallest AIC values.

The ANOVA and DGC tests applied to DE and MDT values demonstrated that brand I was not similar to any other.

If fit factors are considered, only brands I, II and V were similar.

In conclusion, significant differences were observed between the *in vitro* dissolution profiles of meloxicam tablets of different commercial preparations. As meloxicam is a class II BCS drug, interchangeability between commercial products must be demonstrated with *in vivo* bioequivalence studies, which remain to be implemented in our country.
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[^1]: F~critical~ = 1.890.

[^2]: Significant for P \> 0.05.

[^3]: F~critical~ = 2.033.

[^4]: Significant for P \> 0.05.
